Twist Bioscience (TWST) Stock Looks Undervalued On Cash Flow But Overvalued On Sales
Twist Bioscience stock has delivered a very strong 3 year return while the valuation checks send mixed messages about where the shares sit today. The intrinsic value estimate based on a Discounted Cash Flow, or DCF, framework points to upside against the current price, while the market based multiples suggest the stock screens as expensive.
- Over the past 3 years, Twist Bioscience has returned about 444.6%, which puts a lot of expectation into the current share price.
- The investment case can benefit if the company converts its technology and pipeline into durable cash generation. However, any setback in turning revenue into steady free cash flow may weigh heavily on what investors are willing to pay.
- On a composite basis the stock scores 2 out of 6 on value checks, which leans expensive rather than a clear bargain when looking across several valuation angles.
The issue now is whether Twist Bioscience’s recent share price surge leaves enough potential reward to compensate for the risks implied by these conflicting valuation signals.
Scan beyond Twist Bioscience’s 419.5% one year surge and stress test your ideas against 49 high quality undervalued stocks with stronger value signals and more balanced valuation checks.
Is Twist Bioscience Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) approach tries to pin a value on Twist Bioscience by estimating the cash it might generate for shareholders over time. Recent twelve month free cash flow sits at a loss of about $78.1 million, so the whole exercise leans heavily on the idea that cash generation can recover rather than stay deeply negative.
Analyst and model projections here assume that free cash flow not only turns positive but moves into substantial positive territory by the early 2030s. On those assumptions, the DCF framework arrives at an intrinsic value estimate of about $200 per share. At the current market price, this framework suggests the stock trades at roughly a 37.3% discount. In this view, the cash flow model characterizes Twist Bioscience as looking cheap relative to its projected future cash generation despite the present drag from losses.
On these cash flow assumptions, the DCF view is that Twist Bioscience stock currently screens as undervalued.
Our Discounted Cash Flow (DCF) analysis suggests Twist Bioscience is undervalued by 37.3%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.
Does Twist Bioscience Look Pricey on Sales?
P/S works well for Twist Bioscience because investors are focused on revenue potential while the business is still loss making. On this yardstick the stock changes hands at about 18.2x sales, compared with roughly 12.9x for the broader biotechs group and about 13.5x for close peers. That is a clear premium to what the market is paying elsewhere for each dollar of revenue.
The fair P/S ratio estimate sits near 6.4x based on the company’s size, risk profile and industry context. Against that benchmark, the current 18.2x reading implies investors are paying close to three times what this framework flags as a more grounded level. For anyone weighing the DCF upside against today’s trading price, this sales multiple suggests expectations are already running high in the share price.
On the P/S lens, Twist Bioscience stock currently appears overvalued compared with both its fair ratio and sector benchmarks.
See what the numbers say about this price — find out in our valuation breakdown.
The Twist Bioscience Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where that Twist Bioscience valuation gap leaves off. They explain which potential paths for Twist Bioscience's growth, margins and earnings would need to occur for the shares to justify a much higher or lower price than today. These Narratives are available on the stock's Community page. Where a single ratio or model gives you one output, Narratives unpack the future it depends on so you can monitor whether that story is still on track.
One of the top community narratives on Twist Bioscience: 19% overvalued
"Heavy customer concentration, ongoing losses, volatile margins, and stagnant emerging market growth threaten revenue stability, profitability, and long-term competitive positioning..."
Read one of the top narratives on Twist Bioscience
Do you think there's more to the story for Twist Bioscience? Head over to our Community to see what others are saying!
The Bottom Line
Twist Bioscience screens as undervalued on a Discounted Cash Flow (DCF) view, yet looks overvalued on straightforward sales multiples. That clash reflects a simple tension. The intrinsic value model leans on future cash generation improving meaningfully, while the market ratios highlight how much optimism is already embedded in the revenue story. Broader valuation checks remain weak, so the key question is whether Twist Bioscience can convert its technology and pipeline into durable free cash flow before investor enthusiasm for high-priced growth cools.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com